Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.64 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.64 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15668349 | 0.84 | CCNB2 (0.46) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15668123 | 0.84 | CCNB2 (0.49) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL14707494 | 0.83 | CRHBP (0.58) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15668213 | 0.83 | CCNB2 (0.60) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL17771233 | 0.83 | KDR (0.53) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL13552782 | 0.82 | TP53 (0.55) | RORCMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL13044299 | 0.82 | CCNB2 (0.47) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL13552967 | 0.81 | KMT2A (0.46) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15668596 | 0.79 | CCNB2 (0.55) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL17102963 | 0.78 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-2914253-B1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANTBIOSCIENCE INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| WO-2014071298-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2440048-A1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144586-A1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144586-A1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | SMO, SHH, SOS1 | CCNB2 1882/4885CDK1 1121/4885CCNB1 2282/4885 |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | CCNB2 894/4885CDK1 627/4885CCNB1 897/4885 |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | CCNB2 1882/4885CDK1 1121/4885CCNB1 2282/4885 |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | CCNB2 1869/4885CDK1 641/4885CCNB1 2913/4885 |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | CCNB2 894/4885CDK1 627/4885CCNB1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.